• In recent weeks, Dr. Reju-All announced the nationwide rollout of five clinically focused skincare products into select Ulta Beauty stores and online, while Pacsun and Ulta Beauty revealed an exclusive fashion-and-beauty collaboration alongside the opening of a new San Antonio location offering products and salon services.
• Together, these partnerships and footprint expansion moves highlight Ulta Beauty’s push to broaden its assortment, reach younger shoppers, and deepen its presence across both physical and digital channels.
• We’ll now examine how Ulta’s new Pacsun collaboration could influence its existing investment narrative around partnerships, assortment breadth, and growth.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Ulta Beauty Investment Narrative Recap

To own Ulta Beauty, you need to believe the company can keep growing its broad, omnichannel beauty platform while managing rising costs and intensifying competition. The most important near term catalyst remains Ulta’s ability to deepen customer engagement through exclusive brands and partnerships, while a key risk is margin pressure from store expenses, wage inflation, and the eventual Target partnership loss. The latest Pacsun, Dr. Reju-All, and store opening news do not materially change those near term drivers.

The Pacsun x Ulta Beauty collaboration is especially relevant here because it directly supports Ulta’s assortment breadth and Gen Z reach, two areas analysts see as central to sustaining sales and engagement. By tying together fashion, beauty kits, and TikTok Shop distribution, this partnership sits squarely inside Ulta’s catalyst around exclusive offerings and omnichannel presence, even as it unfolds against ongoing concerns about rising store costs and competitive intensity.

But while partnerships like Pacsun help, investors should also be aware of the mounting cost pressures that could quietly weigh on...

Ulta Beauty’s narrative projects $14.9 billion revenue and $1.4 billion earnings by 2029. This requires 5.4% yearly revenue growth and about a $0.2 billion earnings increase from $1.2 billion today.

Uncover how Ulta Beauty's forecasts yield a $627.25 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts see more pressure here, expecting only about US$14.7 billion of revenue and roughly US$1.3 billion of earnings by 2029, so if you worry that rising e commerce competition and sustainability expectations could tighten margins despite partnerships like Pacsun, it is worth comparing their cautious view with more optimistic takes that might be revised once this new collaboration and product news are fully reflected.

Explore 5 other fair value estimates on Ulta Beauty - why the stock might be worth as much as 13% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ulta Beauty research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Ulta Beauty research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ulta Beauty's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.